Tempus AI Stock Gains Momentum as Diagnostics Revenue Climbs 85% YoY

Tempus AI [TEM] is showing impressive execution across its business, with third-quarter 2025 results underscoring accelerating diagnostics demand and improved pricing dynamics. The biotech diagnostics company delivered $334.2 million in quarterly revenue—up 84.7% from the year-ago period—driven by volume growth and higher average reimbursement rates that narrow the competitive gap.

Genomics Business Powers the Growth Engine

The genomics segment is firing on all cylinders. Tempus AI’s genomics revenue jumped 117% year over year to $252.9 million, with oncology and hereditary testing leading the charge. The company processed 217,000 clinical tests, a 33% increase versus the prior year, with oncology revenue reaching $139.5 million and hereditary testing contributing $102.6 million. This mix shift toward higher-value oncology work is a key catalyst for margin expansion.

The Data and services segment, while smaller, is accelerating too. This unit grew 26.1% to $81.3 million, with the Insights sub-segment climbing 37.6% as data licensing and study partnerships pick up steam.

Profitability Path Materializing Despite GAAP Losses

Gross margin strength signals operational leverage ahead. Gross profit more than doubled to $209.9 million on volume gains and improving average selling prices per test. Management highlighted cost discipline and sales force efficiency improvements following portfolio integration.

On an adjusted EBITDA basis—a better read of operational performance—Tempus AI swung to a $1.5 million profit from a year-ago loss. However, GAAP net loss remained substantial at $80.0 million, weighed down by non-cash charges and integration expenses. This gap between adjusted and reported metrics is a common headwind for investors tracking the path to true profitability.

Reimbursement and Regulatory Milestones Building Momentum

Tempus AI is making measurable progress on pricing. Average reimbursement improved by mid-teens percentage points per test in the quarter, a meaningful step toward parity with established peers.

On the regulatory front, approximately one-third of xT CDx volume is already on FDA-approved or Advanced Diagnostic Laboratory Test pathways, with the company planning to migrate the majority through 2026. The xF assay is slated for FDA submission by year-end 2025, followed by the xR assay. Minimal residual disease (MRD) coverage is gradually expanding as reimbursement widens, setting up a multi-year upside scenario.

Data Partnerships Offer Long-Term Revenue Visibility

The Data and services unit is increasingly visible in multi-quarter bookings and Compass CRO awards that tend to convert over time. These multi-year data collaborations add significant backlog but come with elongated conversion cycles—a headwind for near-term reported revenue growth yet a tailwind for future mix and leverage.

With $764.3 million in cash and marketable securities on the balance sheet, Tempus AI has firepower to fund AI compute, regulatory filings and commercial expansion. Management guided for roughly $1.265 billion in full-year 2025 revenue and approximately $20 million in adjusted EBITDA.

Bottom Line: Catalyst-Rich Setup with Execution Risk

Tempus AI is threading the needle between growth and profitability. The genomics revenue acceleration, pricing gains and FDA pathway progress provide multiple near-term catalysts. Yet investors are rightfully cautious around GAAP losses, the timing of data deal conversions and competitive dynamics in diagnostics. The stock merits a watchful stance, with attention on MRD coverage expansion, successful xF regulatory submission and sustained reimbursement momentum through 2026.